These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 25534018)

  • 1. A common building block for the syntheses of amorfrutin and cajaninstilbene acid libraries toward efficient binding with peroxisome proliferator-activated receptors.
    Aidhen IS; Mukkamala R; Weidner C; Sauer S
    Org Lett; 2015 Jan; 17(2):194-7. PubMed ID: 25534018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valuable building block for the synthesis of lunularic acid, hydrangeic acid and their analogues.
    Mukkamala R; Hossain A; Singh Aidhen I
    Nat Prod Res; 2017 May; 31(9):1085-1090. PubMed ID: 28044457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha.
    Gani OA; Sylte I
    J Mol Graph Model; 2008 Sep; 27(2):217-24. PubMed ID: 18547851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virtual screening for PPAR modulators using a probabilistic neural network.
    Derksen S; Rau O; Schneider P; Schubert-Zsilavecz M; Schneider G
    ChemMedChem; 2006 Dec; 1(12):1346-50. PubMed ID: 17066499
    [No Abstract]   [Full Text] [Related]  

  • 5. [Synthesis and PPAR activities of novel phenylacetic acid derivatives containing sulfonamide moiety].
    Yang Y; Yan JF; Fan L; Chen X; Jiang L; Yang DC
    Yao Xue Xue Bao; 2012 Dec; 47(12):1630-9. PubMed ID: 23460969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Synthesis of novel beta-aminoalcohols containing nabumetone moiety with potential antidiabetic activity].
    Zhang K; Yan JF; Tang XM; Liu HP; Fan L; Zhou GM; Yang DC
    Yao Xue Xue Bao; 2011 Apr; 46(4):412-21. PubMed ID: 21751495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of new 8(S)-HETE analogs and their biological evaluation as activators of the PPAR nuclear receptors.
    Liutkus M; Caijo F; Girard AL; Ayral E; Audinot V; Boutin JA; Renard P; Caignard DH; Dacquet C; Ktorza A; Mosset P; Grée R
    J Enzyme Inhib Med Chem; 2010 Oct; 25(5):653-72. PubMed ID: 20518620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and activity evaluation of GK/PPARγ dual-target-directed ligands as hypoglycemic agents.
    Lu J; Lei L; Huan Y; Li Y; Zhang L; Shen Z; Hu W; Feng Z
    ChemMedChem; 2014 May; 9(5):922-7. PubMed ID: 24737574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands and their therapeutic utility.
    Henke BR
    Prog Med Chem; 2004; 42():1-53. PubMed ID: 15003718
    [No Abstract]   [Full Text] [Related]  

  • 11. [Design, synthesis and PPAR agonist activities of novel L-tyrosine derivatives containing phenoxyacetyl moiety].
    Zhou LJ; Yan JF; Zhang K; Fan L; Chen X; Yang DC
    Yao Xue Xue Bao; 2013 Oct; 48(10):1570-8. PubMed ID: 24417084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
    Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
    Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Biology-Based Exploration of Subtype-Selective Agonists for Peroxisome Proliferator-Activated Receptors.
    Miyachi H
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists.
    Mahindroo N; Peng YH; Lin CH; Tan UK; Prakash E; Lien TW; Lu IL; Lee HJ; Hsu JT; Chen X; Liao CC; Lyu PC; Chao YS; Wu SY; Hsieh HP
    J Med Chem; 2006 Oct; 49(21):6421-4. PubMed ID: 17034149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents.
    Itoh T; Murota I; Yoshikai K; Yamada S; Yamamoto K
    Bioorg Med Chem; 2006 Jan; 14(1):98-108. PubMed ID: 16198578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Salicylic acid derivatives as simplified and novel GK small molecule activators].
    Huo LC; Zhang YL; Lei L; Liu SN; Shen ZF; Wang YL; Song HR; Feng ZQ
    Yao Xue Xue Bao; 2013 Apr; 48(4):514-20. PubMed ID: 23833938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of thiadiazole as an antidiabetic agent- a review.
    Datar PA; Deokule TA
    Mini Rev Med Chem; 2014 Feb; 14(2):136-53. PubMed ID: 24387711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptors target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.
    Pirard B
    J Comput Aided Mol Des; 2003 Nov; 17(11):785-96. PubMed ID: 15072437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Important pharmacophoric features of pan PPAR agonists: common chemical feature analysis and virtual screening.
    Sundriyal S; Bharatam PV
    Eur J Med Chem; 2009 Sep; 44(9):3488-95. PubMed ID: 19268404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling.
    Gardner OS; Dewar BJ; Graves LM
    Mol Pharmacol; 2005 Oct; 68(4):933-41. PubMed ID: 16020742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.